Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 8/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14077365 | 1.00 | ALDH1A1 (0.54) | ALDH1A1USP2PTGER4PTGER2MEN1 | |
| SCHEMBL16400568 | 0.85 | ALDH1A1 (0.49) | ALDH1A1USP2PTGER4PTGER2MEN1 | |
| SCHEMBL4944468 | 0.85 | ALDH1A1 (0.49) | ALDH1A1USP2PTGER4PTGER2MEN1 | |
| SCHEMBL19513757 | 0.85 | PTGER4 (0.47) | ALDH1A1USP2PTGER4PTGER2MEN1 | |
| SCHEMBL14069009 | 0.83 | ALDH1A1 (0.69) | ALDH1A1USP2PTGER4PTGER2KMT2A | |
| SCHEMBL17475054 | 0.83 | PTGER4 (0.56) | ALDH1A1PTGER4PTGER2PTGER3 | |
| SCHEMBL4691930 | 0.83 | PTGER4 (0.56) | ALDH1A1PTGER4PTGER2PTGER3 | |
| SCHEMBL16401337 | 0.83 | PTGER4 (0.49) | ALDH1A1PTGER4PTGER2MEN1KMT2A | |
| SCHEMBL4946290 | 0.83 | PTGER4 (0.49) | ALDH1A1PTGER4PTGER2MEN1KMT2A | |
| SCHEMBL4943912 | 0.83 | PTGER4 (0.56) | ALDH1A1PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| US-10729810-B2 | Methods, systems, and compositions for promoting bone growth | CAYMAN CHEMICAL COMPANY, INC (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3235817-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-3235817-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3235817-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688627-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9676712-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676712-B2 | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144584-A2 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| EP-1603874-B1 | G-LACTAM DERIVATIVES AS PROSTAGLANDIN AGONISTS | SERONO LAB (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7276531-B2 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-10-02 | — | — | US | disclosed |
| US-20060194865-A1 | G-lactam derivatives as prostaglandin agonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2006-08-31 | — | — | US | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194865-A1 | G-lactam derivatives as prostaglandin agonists | PTGIS, PTGIR, PTGES | ALDH1A1 2004/4885USP2 3042/4885PTGER4 12/4885 |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | ALDH1A1 1403/4885USP2 3731/4885PTGER4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.